Ogston D, Ogston C M, Ratnoff O D, Forbes C D
J Clin Invest. 1969 Oct;48(10):1786-801. doi: 10.1172/JCI106145.
As demonstrated by others, fibrinolytic activity was generated in diluted, acidified normal plasma exposed to kaolin, a process requiring Hageman factor (Factor XII). Generation was impaired by adsorbing plasma with glass or similar agents under conditions which did not deplete its content of Hageman factor or plasminogen. The defect could be repaired by addition of a noneuglobulin fraction of plasma or an agent or agents eluted from diatomaceous earth which had been exposed to normal plasma. The restorative agent, tentatively called Hageman factor-cofactor, was partially purified by chromatography and had an apparent molecular weight of approximately 165,000. It could be distinguished from plasma thromboplastin antecedent (Factor XI) and plasma kallikrein, other substrates of Hageman factor, and from the streptokinase-activated pro-activator of plasminogen. Evidence is presented that an additional component may be needed for the generation of fibrinolytic activity in mixtures containing Hageman factor, HF-cofactor, and plasminogen.The long-recognized generation of plasmin activity in chloroform-treated euglobulin fractions of plasma was found to be dependent upon the presence of Hageman factor. Whether chloroform activation of plasminogen requires Hageman factor-cofactor was not determined, but glass-adsorbed plasma, containing Hageman factor and plasminogen, did not generate appreciable fibrinolytic or caseinolytic activity. These studies emphasize the complex nature of the mechanisms which lead to the generation of plasmin in human plasma.
正如其他人所证明的,在暴露于高岭土的稀释、酸化正常血浆中会产生纤溶活性,这一过程需要哈格曼因子(因子 XII)。在不消耗其哈格曼因子或纤溶酶原含量的条件下,用玻璃或类似试剂吸附血浆会损害纤溶活性的产生。通过添加血浆的非优球蛋白部分或从暴露于正常血浆的硅藻土中洗脱的一种或多种试剂,可以修复该缺陷。这种暂称为哈格曼因子辅因子的修复剂通过色谱法进行了部分纯化,其表观分子量约为 165,000。它可以与血浆凝血活酶前体(因子 XI)、血浆激肽释放酶(哈格曼因子的其他底物)以及链激酶激活的纤溶酶原激活剂区分开来。有证据表明,在含有哈格曼因子、HF 辅因子和纤溶酶原的混合物中,产生纤溶活性可能还需要一种额外的成分。长期以来人们认识到,血浆经氯仿处理的优球蛋白部分中纤溶酶活性的产生依赖于哈格曼因子的存在。氯仿激活纤溶酶原是否需要哈格曼因子辅因子尚未确定,但含有哈格曼因子和纤溶酶原的玻璃吸附血浆不会产生明显的纤溶或酪蛋白溶解活性。这些研究强调了导致人血浆中纤溶酶产生的机制的复杂性。